Literature DB >> 29746416

CRISPR GENOME SURGERY IN THE RETINA IN LIGHT OF OFF-TARGETING.

Galaxy Y Cho1,2,3, Kellie A Schaefer4, Alexander G Bassuk5, Stephen H Tsang1,2,3,6, Vinit B Mahajan4,7.   

Abstract

PURPOSE: Recent concerns regarding the clinical utilization of clustered regularly interspaced short palindromic repeats (CRISPR) involve uncertainties about the potential detrimental effects that many arise due to unintended genetic changes, as in off-target mutagenesis, during CRISPR genome surgery. This review gives an overview of off-targeting detection methods and CRISPR's place in the clinical setting, specifically in the field of ophthalmology.
RESULTS: As CRISPR utilization in the laboratory setting has increased, knowledge regarding CRISPR mechanisms including its off-target effects has also increased. Although a perfect method for achieving 100% specificity is yet to be determined, the past few years have seen many developments in off-targeting detection and in increasing efficacy of CRISPR tools.
CONCLUSION: The CRISPR system has high potential to be an invaluable therapeutic tool as it has the ability to modify and repair pathogenic retinal lesions. Although it is not yet a perfect system, with further efforts to improve its specificity and efficacy along with careful screening of off-target mutations, CRISPR-mediated genome surgery potential can become maximized and applied to patients.

Entities:  

Mesh:

Year:  2018        PMID: 29746416      PMCID: PMC6054556          DOI: 10.1097/IAE.0000000000002197

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  116 in total

1.  Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity.

Authors:  F Ann Ran; Patrick D Hsu; Chie-Yu Lin; Jonathan S Gootenberg; Silvana Konermann; Alexandro E Trevino; David A Scott; Azusa Inoue; Shogo Matoba; Yi Zhang; Feng Zhang
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

2.  Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells.

Authors:  Xuebing Wu; David A Scott; Andrea J Kriz; Anthony C Chiu; Patrick D Hsu; Daniel B Dadon; Albert W Cheng; Alexandro E Trevino; Silvana Konermann; Sidi Chen; Rudolf Jaenisch; Feng Zhang; Phillip A Sharp
Journal:  Nat Biotechnol       Date:  2014-04-20       Impact factor: 54.908

3.  Targeted genome editing in human cells using CRISPR/Cas nucleases and truncated guide RNAs.

Authors:  Yanfang Fu; Deepak Reyon; J Keith Joung
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

4.  Correction of a pathogenic gene mutation in human embryos.

Authors:  Hong Ma; Nuria Marti-Gutierrez; Sang-Wook Park; Jun Wu; Yeonmi Lee; Keiichiro Suzuki; Amy Koski; Dongmei Ji; Tomonari Hayama; Riffat Ahmed; Hayley Darby; Crystal Van Dyken; Ying Li; Eunju Kang; A-Reum Park; Daesik Kim; Sang-Tae Kim; Jianhui Gong; Ying Gu; Xun Xu; David Battaglia; Sacha A Krieg; David M Lee; Diana H Wu; Don P Wolf; Stephen B Heitner; Juan Carlos Izpisua Belmonte; Paula Amato; Jin-Soo Kim; Sanjiv Kaul; Shoukhrat Mitalipov
Journal:  Nature       Date:  2017-08-02       Impact factor: 49.962

Review 5.  Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases.

Authors:  Shengdar Q Tsai; J Keith Joung
Journal:  Nat Rev Genet       Date:  2016-05       Impact factor: 53.242

Review 6.  Translating induced pluripotent stem cells from bench to bedside: application to retinal diseases.

Authors:  Alona O Cramer; Robert E MacLaren
Journal:  Curr Gene Ther       Date:  2013-04       Impact factor: 4.391

7.  Gene Therapy for Leber Hereditary Optic Neuropathy: Initial Results.

Authors:  William J Feuer; Joyce C Schiffman; Janet L Davis; Vittorio Porciatti; Phillip Gonzalez; Rajeshwari D Koilkonda; Huijun Yuan; Anil Lalwani; Byron L Lam; John Guy
Journal:  Ophthalmology       Date:  2015-11-19       Impact factor: 12.079

8.  Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial.

Authors:  Nicola G Ghazi; Emad B Abboud; Sawsan R Nowilaty; Hisham Alkuraya; Abdulrahman Alhommadi; Huimin Cai; Rui Hou; Wen-Tao Deng; Sanford L Boye; Abdulrahman Almaghamsi; Fahad Al Saikhan; Hassan Al-Dhibi; David Birch; Christopher Chung; Dilek Colak; Matthew M LaVail; Douglas Vollrath; Kirsten Erger; Wenqiu Wang; Thomas Conlon; Kang Zhang; William Hauswirth; Fowzan S Alkuraya
Journal:  Hum Genet       Date:  2016-01-29       Impact factor: 4.132

9.  GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases.

Authors:  Shengdar Q Tsai; Zongli Zheng; Nhu T Nguyen; Matthew Liebers; Ved V Topkar; Vishal Thapar; Nicolas Wyvekens; Cyd Khayter; A John Iafrate; Long P Le; Martin J Aryee; J Keith Joung
Journal:  Nat Biotechnol       Date:  2014-12-16       Impact factor: 54.908

10.  Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.

Authors:  Robert E MacLaren; Markus Groppe; Alun R Barnard; Charles L Cottriall; Tanya Tolmachova; Len Seymour; K Reed Clark; Matthew J During; Frans P M Cremers; Graeme C M Black; Andrew J Lotery; Susan M Downes; Andrew R Webster; Miguel C Seabra
Journal:  Lancet       Date:  2014-01-16       Impact factor: 79.321

View more
  6 in total

1.  CAPN5 genetic inactivation phenotype supports therapeutic inhibition trials.

Authors:  Katherine J Wert; Susanne F Koch; Gabriel Velez; Chun-Wei Hsu; MaryAnn Mahajan; Alexander G Bassuk; Stephen H Tsang; Vinit B Mahajan
Journal:  Hum Mutat       Date:  2019-08-26       Impact factor: 4.878

Review 2.  Attenuation of Inherited and Acquired Retinal Degeneration Progression with Gene-based Techniques.

Authors:  Galaxy Y Cho; Kyle Bolo; Karen Sophia Park; Jesse D Sengillo; Stephen H Tsang
Journal:  Mol Diagn Ther       Date:  2019-02       Impact factor: 4.074

Review 3.  STEM CELL THERAPIES, GENE-BASED THERAPIES, OPTOGENETICS, AND RETINAL PROSTHETICS: Current State and Implications for the Future.

Authors:  Edward H Wood; Peter H Tang; Irina De la Huerta; Edward Korot; Stephanie Muscat; Daniel A Palanker; George A Williams
Journal:  Retina       Date:  2019-05       Impact factor: 4.256

Review 4.  Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa.

Authors:  Da Meng; Sara D Ragi; Stephen H Tsang
Journal:  Mol Ther       Date:  2020-08-25       Impact factor: 11.454

5.  Knockout of Anopheles stephensi immune gene LRIM1 by CRISPR-Cas9 reveals its unexpected role in reproduction and vector competence.

Authors:  Ehud Inbar; Abraham G Eappen; Robert T Alford; William Reid; Robert A Harrell; Maryam Hosseini; Sumana Chakravarty; Tao Li; B Kim Lee Sim; Peter F Billingsley; Stephen L Hoffman
Journal:  PLoS Pathog       Date:  2021-11-16       Impact factor: 7.464

6.  Comprehensive off-target analysis of dCas9-SAM-mediated HIV reactivation via long noncoding RNA and mRNA profiling.

Authors:  Yonggang Zhang; Gustavo Arango; Fang Li; Xiao Xiao; Raj Putatunda; Jun Yu; Xiao-Feng Yang; Hong Wang; Layne T Watson; Liqing Zhang; Wenhui Hu
Journal:  BMC Med Genomics       Date:  2018-09-10       Impact factor: 3.063

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.